Skip to main content

Table 5 Logistic regression analyses predicting probability of prostate cancer in subjects with tPSA 4–10 ng/mL

From: Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study

Predictors AUC of individual predictor variable (95% CI);
P value*
Bivariate analysis
OR(95%CI);
P value
Multivariate analysis
Base model **
OR (95%CI); P value
Base model + %p2PSA
OR (95% CI); P value
Base model + PHI
OR(95%CI); P value
Age 0.63
(0.51–0.74)
0.235
1.069
(1.01–1.13);
0.031
1.081
(1.02–1.15); 0.013
1.084
(1.01–1.16); 0.018
1.084
(1.01–1.16); 0.018
tPSA, ng/mL 0.50
(0.38–0.61)
1.024
(0.76–1.38); 0.875
1.615
(0.66–3.86); 0.281
1.384
(0.49 − 3.88); 0.536
1.243
(0.44–3.48); 0.679
fPSA 0.59
(0.47–0.70) 0.418
0.529
(0.18–1.53); 0.240
0.038
(0.00–11.2); 0.261
0.070
(0.00–53.9); 0.433
0.071
(0.00–56.5); 0.437
%fPSA 0.63
(0.52–0.74) 0.090
0.961
(0.89–1.03); 0.284
1.155
(0.80–1.66); 0.448
1.108
(0.73–1.69); 0.631
1.108
(0.73–1.69); 0.632
p2PSA, pg/mL 0.59
(0.47–0.70) 0.286
1.023
(1.00–1.05); 0.089
%p2PSA 0.70
(0.59–0.81) 0.038
1.020
(1.00–1.04); 0.007
1.022
(1.01–1.04); 0.007
PHI 0.70
(0.59–0.81) 0.020
1.743
(1.19–2.56); 0.005
1.760
(1.17–2.64); 0.006
AUC of multivariate models (95% CI); 0.682
(0.57–0.78)
0.003
0.784
(0.68–0.87)
< 0.001
0.787
(0.68–0.87)
< 0.001
Gain in predictive accuracy (95% CI);
P value
0.102
(− 0.00–0.21);
0.054
0.104
(0.00–0.21);
0.048
  1. AUC, area under the receiver operating characteristic curve; PSA, prostate-specific antigen; fPSA, free PSA; p2PSA, [-2]proPSA; PHI, prostate health index; tPSA, total PSA, OR, odds ratio; CI, confidence interval
  2. *P value: Comparison of AUC using tPSA as standard
  3. **Base model includes age, tPSA, fPSA and %fPSA
  4. P value to be statiscally significant with bolditalics